Delavirdine increases drug exposure of ritonavir-boosted protease inhibitors.
Harris
Marianne
M
Alexander
Chris
C
O'Shaughnessy
Michael
M
Montaner
Julio S G
JS
D019380:Anti-HIV Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D002219:Carbamates; D020008:Delavirdine / Q000493:pharmacokinetics* / Q000627:therapeutic use; D004357:Drug Synergism; D005663:Furans; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000493:pharmacokinetics* / Q000627:therapeutic use; D006801:Humans; D061466:Lopinavir; D011744:Pyrimidinones / Q000493:pharmacokinetics / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000493:pharmacokinetics* / Q000627:therapeutic use; D019438:Ritonavir / Q000493:pharmacokinetics* / Q000627:therapeutic use; D013449:Sulfonamides / Q000493:pharmacokinetics / Q000627:therapeutic use
D019380:Anti-HIV Agents; D002219:Carbamates; D005663:Furans; D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D018894:Reverse Transcriptase Inhibitors; D013449:Sulfonamides; D061466:Lopinavir; C095108:amprenavir; D020008:Delavirdine; D019438:Ritonavir